Multimodale behandeling kan vroege prostaatkanker ondetecteerbaar maken

Metastatic prostate cancer is considered to be incurable. But now a pilot trial, in 20 selected men with early-stage metastatic prostate cancer, has shown that aggressive multimodality treatment with hormone therapy, surgery, and radiation “can eliminate detectable disease.”

Overall, 20% of the patients treated reached the primary endpoint — undetectable prostate-specific antigen (PSA) and noncastrate levels of testosterone at 20 months, which the authors described as “no evidence of disease” (NED).

This endpoint “could not have been achieved with any single therapy alone,” they note.

“Although longer follow-up is needed to assess durability, this binary end point represents a first step toward establishing a paradigm of cure in patients with low-volume metastatic disease,” they conclude.

Read the abstract in Urology

A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer


Door de site te blijven gebruiken, ga je akkoord met het gebruik van cookies. meer informatie

Deze site is standaard ingesteld op 'cookies toestaan", om je de beste mogelijke blader ervaring te geven. Als je deze site blijft gebruiken zonder je cookie instellingen te wijzigen, of als je klikt op "Accepteren" hieronder, dan geef je toestemming voor het gebruik van Cookies.